GLOBUS MEDICAL INC 10-Q

Item 5. Other Information Form 8-K Item 1.01 Disclosure On August 4, 2021, the Company entered into an amendment to the Credit Agreement with Citizens Bank, N.A. (the “Credit Agreement Amendment”) to, among other things, extend the maturity date of the Company’s Revolving Credit Facility to August 3, 2022. The foregoing description of the Credit Agreement Amendment is qualified in its entirety by reference to the text of the Credit Agreement Amendment, which is being filed herewith as Exhibit 10.1 and the terms of which are incorporated herein by reference. Form 8-K Item 2.03 Disclosure The information provided under “Form 8-K Item 1.01 Disclosure” is incorporated by reference into this Item 2.03. Form 8-K Item 5.03 Disclosure On July 31, 2021, the board of directors of the Company approved an amendment (the “Bylaw Amendment”) to the Amended and Restated Bylaws of the Company (the “Bylaws”), which became effective immediately. The Bylaw Amendment added a new section 8.14 to the Bylaws which limits, to the fullest extent permitted by law, the forum for the resolution of any complaint under the Securities Act of 1933, as amended, to the federal district courts of the United States of America. The foregoing summary of the Bylaw Amendment is qualified in its entirety by reference to the text of the Bylaw Amendment, which is being filed herewith as Exhibit 3.1 and the terms of which are incorporated herein by reference. Item 6. Exhibits The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated in parentheses. 33 Table of Contents Exhibit No. Item 3.1* Amendment to Bylaws effective as of July 31, 2021. 10.1* First Amendment to Credit Agreement, dated as of August 4, 2021, by and among Globus Medical, Inc., Globus Medical North America, Inc., and Citizens Banks, N.A. 31.1* Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification by Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32** Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 99.1 Globus Medical, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the SEC on June 4, 2021). 101.INS* XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH* XBRL Taxonomy Extension Schema Document 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) * Filed herewith. ** Furnished herewith. ‎ 34 Table of Contents SIGNA TURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GLOBUS MEDICAL, INC. Dated: August 4, 2021 /s/ DAVID M. DEMSKI David M. Demski Chief Executive Officer President (Principal Executive Officer) Dated: August 4, 2021 /s/ KEITH PFEIL Keith Pfeil Chief Financial Officer Chief Accounting Officer Senior Vice President (Principal Financial Officer) 35